non-small cell lung cancer
Conditions
Interventions
Control group:Placebo
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Postoperative patients with stage I non-small cell lung cancer diagnosed by pathology or cytology; 2. Enroll in the group within two weeks after thoracoscopy; 3. Aged 18-75 years; 4. Physical condition score ECOG 0-2 points; 5. Estimated survival period >= 6 months; 6. Neutrophils>1.5x10^9/L, platelets > 100x10^9/L, hemoglobin>9.0g/dl; normal bilirubin or < 1.5xULN; AST (SGOT), ALT (SGPT)< 2.5xULN; serum creatinine < 1.5xULN.
Exclusion criteria
Exclusion criteria: 1. Patients who received neoadjuvant chemotherapy before surgery; 2. Those who intend to receive radiotherapy, chemotherapy, targeted drug therapy and other treatment methods within 1 month after surgery; 3. Patients with severe complications such as pulmonary embolism, respiratory failure, and myocardial infarction during the perioperative period; 4. In other clinical trials; 5. Patients during pregnancy or lactation; 6. Patients with a history of mental illness that is difficult to control; 7. Those who are allergic to study drugs; 8. Those who cannot understand and refuse to sign the informed consent form; 9. Those who cannot cooperate with the scale data collector.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom threshold events reduction rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of life;6 minutes walk test;lung function;mean symptom interference; | — |
Countries
China
Contacts
Public ContactHou Wei
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed